SCHEMBL1403601

SCHEMBL1403601

O=C/C=C/c1cccc2c1OCO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.48
GSK3B P49841 1/20 0.48
KDM4E B2RXH2 1/20 0.45
CDK4 P11802 4/20 0.43
CCND1 P24385 4/20 0.43
ABCG2 Q9UNQ0 1/20 0.40
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
CCNB2 O95067 2/20 0.36
CDK1 P06493 2/20 0.36
CCNB1 P14635 2/20 0.36
CCNB3 Q8WWL7 2/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 2/20 0.35
TRPA1 O75762 1/20 0.35
ALOX5 P09917 1/20 0.35
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1403602 1.00 MAOB (0.48) MAOBGSK3BKDM4ECDK4CCND1
SCHEMBL29706697 0.83 GSK3B (0.54) MAOBGSK3BKDM4EABCG2ALDH1A1
SCHEMBL161792 0.83 GSK3B (0.54) MAOBGSK3BKDM4EABCG2ALDH1A1
SCHEMBL97241 0.79 MAOB (0.43) MAOBGSK3BKDM4EABCG2ALDH1A1
SCHEMBL97242 0.79 MAOB (0.43) MAOBGSK3BKDM4EABCG2ALDH1A1
SCHEMBL13972664 0.78 MAOB (0.50) MAOBGSK3BKDM4EABCG2PKM
SCHEMBL3570479 0.77 MAOB (0.60) MAOBGSK3BKDM4EABCG2ALDH1A1
SCHEMBL4168160 0.77 MAOB (0.47) MAOBGSK3BKDM4EABCG2ALDH1A1
SCHEMBL3570478 0.77 MAOB (0.60) MAOBGSK3BKDM4EABCG2ALDH1A1
SCHEMBL4168158 0.77 MAOB (0.47) MAOBGSK3BKDM4EABCG2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10899750-B2 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity ANGION BIOMEDICA CORP. (US) 2021-01-26 US disclosed
US-20180009793-A1 METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP (US) 2018-01-11 US disclosed
US-20180009793-A1 METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP (US) 2018-01-11 US disclosed
US-9663471-B2 Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity ANGION BIOMEDICA CORPORATION (US) 2017-05-30 US disclosed
US-9663471-B2 Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity ANGION BIOMEDICA CORPORATION (US) 2017-05-30 US disclosed
US-9663471-B2 Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity ANGION BIOMEDICA CORPORATION (US) 2017-05-30 US disclosed
EP-2292227-B1 Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity ANGION BIOMEDICA CORP (US) 2016-08-24 EP disclosed
EP-2292227-B1 Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity ANGION BIOMEDICA CORP (US) 2016-08-24 EP disclosed
US-20140256780-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORPORATION (US) 2014-09-11 US disclosed
US-20140256727-A1 METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP. (US) 2014-09-11 US disclosed
US-7250437-B2 Small molecule modulators of hepatocyte growth factor (scatter factor) activity ANGION BIOMEDICA CORP. (US) 2007-07-31 US disclosed
US-7250437-B2 Small molecule modulators of hepatocyte growth factor (scatter factor) activity ANGION BIOMEDICA CORP. (US) 2007-07-31 US disclosed
US-7192976-B2 3-substituted pyrazoles; cell proliferation and angiogenesis promoters; antiapoptotosis and antifibrosis activity ANGION BIOMEDICA CORPORATION (US) 2007-03-20 US disclosed
US-7192976-B2 3-substituted pyrazoles; cell proliferation and angiogenesis promoters; antiapoptotosis and antifibrosis activity ANGION BIOMEDICA CORPORATION (US) 2007-03-20 US disclosed
US-7192976-B2 3-substituted pyrazoles; cell proliferation and angiogenesis promoters; antiapoptotosis and antifibrosis activity ANGION BIOMEDICA CORPORATION (US) 2007-03-20 US disclosed
EP-1572199-A2 PYRAZOLE DERIVATIVES MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY Angion Biomedica Corp. (US) 2005-09-14 EP disclosed
US-20050192331-A1 Administering 3-substituted pyrazoles for therapy of fibrotic liver disease; hepatic isehemia-reperfusion injury; cerebral infarction; ischemic heart disease; renal disease; lung (pulmonary) fibrosis; liver fibrosis associated with hepatitis C, hepatitis B, delta hepatitis, chronic alcoholism ANGION BIOMEDICA CORP. 2005-09-01 US disclosed
US-20050113369-A1 Pyrrazoles connnected to a carbocyclic ring by a vinylene, butadienylene or hexatrienylene bridge, e.g. 3(5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole; compounds exhibit antifibrotic and antiapoptotic activities ANGION BIOMEDICA CORP. 2005-05-26 US disclosed
US-20040180882-A1 3-substituted pyrazoles; cell proliferation and angiogenesis promoters; antiapoptotosis and antifibrosis activity NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-09-16 US disclosed
WO-2004058721-A2 PYRAZOLE DERIVATIVES MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113369-A1 Pyrrazoles connnected to a carbocyclic ring by a vinylene, butadienylene or hexatrienylene bridge, e.g. 3(5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole; compounds exhibit antifibrotic and antiapoptotic activities HGF, HDGF, HGFAC MAOB 3308/4885GSK3B 2757/4885KDM4E 4079/4885
US-20140256727-A1 METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, HGFAC MAOB 1632/4885GSK3B 1068/4885KDM4E 4796/4885
US-10899750-B2 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity HGF, HDGF, HGFAC MAOB 2089/4885GSK3B 925/4885KDM4E 4780/4885
US-20050192331-A1 Administering 3-substituted pyrazoles for therapy of fibrotic liver disease; hepatic isehemia-reperfusion injury; cerebral infarction; ischemic heart disease; renal disease; lung (pulmonary) fibrosis; liver fibrosis associated with hepatitis C, hepatitis B, delta hepatitis, chronic alcoholism HGF, HDGF, PDGFRB MAOB 308/4885GSK3B 428/4885KDM4E 4794/4885
US-20180009793-A1 METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, HGFAC MAOB 1632/4885GSK3B 1068/4885KDM4E 4796/4885
US-20140256780-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, MET MAOB 2066/4885GSK3B 1150/4885KDM4E 4526/4885
US-20040180882-A1 3-substituted pyrazoles; cell proliferation and angiogenesis promoters; antiapoptotosis and antifibrosis activity HGF, HDGF, VEGFA MAOB 1917/4885GSK3B 598/4885KDM4E 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.